💉 A potential threat to the world's generics supply; Pfizer, BioNTech's promising combo vaccine; Sanofi's spin-off of its consumer health business

#459 | Malarial protein discoveries; A phage diet for cells; Migraines in your genes

Oct 27, 2023

∙ Paid

Hello, and welcome to our free Friday edition of The Kable. Today, we kick things off with good news on the respiratory virus vaccine front. Pfizer and BioNTech have announced positive results from phase 1/2 studies of their mRNA-based combo vaccine, which generated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. A phase 3 t…

💉 A potential threat to the world's generics supply; Pfizer, BioNTech's promising combo vaccine; Sanofi's spin-off of its consumer health business

#459 | Malarial protein discoveries; A phage diet for cells; Migraines in your genes

This post is for paid subscribers